A neutralization epitope in the hepatitis C virus E2 glycoprotein interacts with host entry factor CD81

Area of Science:

• Virology
• Immunology
• Vaccine Development

Background:

• Effective vaccine design requires identifying immunogenic targets for neutralizing antibodies.
• Hepatitis C virus (HCV) poses a significant global health challenge, necessitating novel therapeutic and preventative strategies.

Purpose of the Study:

• To characterize a specific epitope on the HCV E2 protein recognized by a neutralizing antibody (1H8).
• To investigate the role of this epitope in antibody binding and interaction with the host entry factor CD81.
• To confirm the in vivo immunogenicity of this epitope in patients with chronic HCV infection.

Main Methods:

• Monoclonal antibody (1H8) characterization to identify its target epitope on the HCV E2 protein.
• Epitope mapping to determine critical amino acid residues for antibody binding and CD81 interaction.
• Detection and analysis of "1H8-like" antibodies in plasma samples from chronic HCV patients.

Main Results:

• The 1H8 antibody targets an epitope on the E2 protein between residues A524 and W529.
• Specific residues (A524, P525, Y527, W529) are vital for antibody binding, while others (T526, Y527, W529) mediate CD81 interaction.
• "1H8-like" antibodies were detected in chronic HCV patients, with some appearing nearly two years post-infection, confirming in vivo immunogenicity.

Conclusions:

• The identified epitope is a critical target for neutralizing antibodies against HCV.
• This epitope's dual role in antibody binding and host cell entry provides insights into viral neutralization mechanisms.
• The findings support the potential of this epitope as a target for developing effective HCV vaccines.